Department of Orthopedic and Trauma Surgery, Students' Scientific Research Center (SSRC), Exceptional Talent Development Center (ETDC), Tehran University of Medical Sciences (TUMS), Shariati Hospital, Tehran, Islamic Republic of Iran.
J Endocrinol Invest. 2012 Dec;35(11):992-5. doi: 10.3275/8617. Epub 2012 Sep 24.
Osteoporotic fractures are a crucial cause of morbidity and mortality in patients with fragility fractures and impose huge economic burden on health care services. Orthopedic surgeons are often the only clinicians seen by the patients with osteoporotic fractures. The improvement in osteoporosis management is an urgent require; therefore, the aim of this study was to determine the efficacy of consultation with an endocrinologist in osteoporosis management of patients with a fragility fracture.
This survey was undertaken in three phases that focused on patients with osteoporotic fractures who were admitted to five tertiary care, level-I, trauma hospital. Patients were evaluated through a questionnaire which was designed to determine whether physicians manage underlying osteoporosis.
The number of patients who underwent a bone mineral density test increased from a rate of 3.6% to 91% after the intervention, as calcium and vitamin D supplementation from 18% to 92%, bisphosphonate prescription from 0.5% to 83%. Also, the overall medication usage increased from 9% to 87%. A small number of patients (3%) were followed up in contrast to a rate of 73% in the third phase.
Orthopedic surgeons are not completely engaged in osteoporosis care for patients with a fragility fracture; therefore, a consultation with an endocrinologist is required to enable orhopedic surgeons to provide an effective osteoporosis care for their patients with an osteoporotic fracture.
骨质疏松性骨折是脆性骨折患者发病率和死亡率的重要原因，并给医疗保健服务带来巨大的经济负担。骨科医生通常是骨质疏松性骨折患者唯一就诊的临床医生。改善骨质疏松症的管理是当务之急，因此，本研究旨在确定咨询内分泌医生对脆性骨折患者骨质疏松症管理的疗效。
这项调查分三个阶段进行，重点关注在五家三级护理、一级创伤医院住院的骨质疏松性骨折患者。通过问卷评估患者，旨在确定医生是否管理潜在的骨质疏松症。
在干预后，接受骨密度测试的患者比例从 3.6%增加到 91%，钙和维生素 D 补充从 18%增加到 92%，双膦酸盐处方从 0.5%增加到 83%。此外，总体用药率从 9%增加到 87%。与第三阶段的 73%相比，只有少数患者（3%）接受了随访。
骨科医生并未完全参与脆性骨折患者的骨质疏松症护理，因此需要咨询内分泌医生，以便骨科医生为骨质疏松性骨折患者提供有效的骨质疏松症护理。
